CN102406939A - 提高难溶性药物溶解性能以提高生物利用度的方法 - Google Patents
提高难溶性药物溶解性能以提高生物利用度的方法 Download PDFInfo
- Publication number
- CN102406939A CN102406939A CN 201010291743 CN201010291743A CN102406939A CN 102406939 A CN102406939 A CN 102406939A CN 201010291743 CN201010291743 CN 201010291743 CN 201010291743 A CN201010291743 A CN 201010291743A CN 102406939 A CN102406939 A CN 102406939A
- Authority
- CN
- China
- Prior art keywords
- surfactant
- insoluble drug
- medicine
- micronized
- micronization processes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 104
- 238000000034 method Methods 0.000 title claims abstract description 92
- 229940079593 drug Drugs 0.000 claims abstract description 63
- 239000004094 surface-active agent Substances 0.000 claims abstract description 45
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 40
- 229960000227 nisoldipine Drugs 0.000 claims description 40
- 230000008569 process Effects 0.000 claims description 40
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 26
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 26
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 25
- 229960002297 fenofibrate Drugs 0.000 claims description 13
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 13
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 12
- -1 Polyoxyethylene Polymers 0.000 claims description 12
- 229960001680 ibuprofen Drugs 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 8
- 229960000715 nimodipine Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 6
- 229960001597 nifedipine Drugs 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 229960003580 felodipine Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 3
- 239000013067 intermediate product Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229960000698 nateglinide Drugs 0.000 claims description 3
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 3
- 229960001783 nicardipine Drugs 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 2
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 claims description 2
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 claims description 2
- 235000011572 Pyrus ussuriensis Nutrition 0.000 claims description 2
- 244000173166 Pyrus ussuriensis Species 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- 229960004346 glimepiride Drugs 0.000 claims description 2
- 229960004427 isradipine Drugs 0.000 claims description 2
- 229960005425 nitrendipine Drugs 0.000 claims description 2
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 claims description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 2
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 claims description 2
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 claims description 2
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000843 powder Substances 0.000 abstract description 8
- 239000003960 organic solvent Substances 0.000 abstract description 3
- 239000012467 final product Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000013341 scale-up Methods 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 32
- 238000005516 engineering process Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 230000008859 change Effects 0.000 description 8
- 238000003672 processing method Methods 0.000 description 6
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 5
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 description 5
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 102000008482 12E7 Antigen Human genes 0.000 description 4
- 108010020567 12E7 Antigen Proteins 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000007962 solid dispersion Substances 0.000 description 4
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001599 direct drying Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007561 laser diffraction method Methods 0.000 description 2
- 229960001652 norethindrone acetate Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000006253 efflorescence Methods 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229940089934 grifulvin v Drugs 0.000 description 1
- 229940089931 gris-peg Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 238000010248 power generation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010291743 CN102406939B (zh) | 2010-09-26 | 2010-09-26 | 提高难溶性药物溶解性能以提高生物利用度的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010291743 CN102406939B (zh) | 2010-09-26 | 2010-09-26 | 提高难溶性药物溶解性能以提高生物利用度的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102406939A true CN102406939A (zh) | 2012-04-11 |
CN102406939B CN102406939B (zh) | 2013-05-08 |
Family
ID=45909472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010291743 Active CN102406939B (zh) | 2010-09-26 | 2010-09-26 | 提高难溶性药物溶解性能以提高生物利用度的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102406939B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104042562A (zh) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | 一种罗红霉素的新固体制剂 |
CN105168175A (zh) * | 2015-08-25 | 2015-12-23 | 瑞阳制药有限公司 | 尼索地平胶囊及其制备方法 |
CN105168169A (zh) * | 2014-06-18 | 2015-12-23 | 山东新时代药业有限公司 | 一种吉非替尼片剂及其制备方法 |
CN109694899A (zh) * | 2019-02-20 | 2019-04-30 | 扬州倍加洁日化有限公司 | 一种含有chg成分的湿巾产品中微生物限度的检测方法 |
CN110420191A (zh) * | 2019-09-06 | 2019-11-08 | 北京兴源联合医药科技有限公司 | 一种包含左甲状腺素钠的口腔崩解片 |
CN110563635A (zh) * | 2019-09-19 | 2019-12-13 | 合肥立方制药股份有限公司 | 二氢吡啶类降压药物原料药微粉化的新方法 |
CN111481514A (zh) * | 2019-01-25 | 2020-08-04 | 鲁南制药集团股份有限公司 | 一种治疗高血脂的片剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931159A (zh) * | 2005-09-16 | 2007-03-21 | 天津药物研究院 | 艾拉莫德微粉化及口服速释制剂 |
CN101675944A (zh) * | 2008-09-16 | 2010-03-24 | 杭州华东医药集团生物工程研究所有限公司 | 含有黄杞叶提取物的组合物及制备方法 |
-
2010
- 2010-09-26 CN CN 201010291743 patent/CN102406939B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931159A (zh) * | 2005-09-16 | 2007-03-21 | 天津药物研究院 | 艾拉莫德微粉化及口服速释制剂 |
CN101675944A (zh) * | 2008-09-16 | 2010-03-24 | 杭州华东医药集团生物工程研究所有限公司 | 含有黄杞叶提取物的组合物及制备方法 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104042562A (zh) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | 一种罗红霉素的新固体制剂 |
CN105168169A (zh) * | 2014-06-18 | 2015-12-23 | 山东新时代药业有限公司 | 一种吉非替尼片剂及其制备方法 |
CN105168169B (zh) * | 2014-06-18 | 2019-08-16 | 山东新时代药业有限公司 | 一种吉非替尼片剂及其制备方法 |
CN105168175A (zh) * | 2015-08-25 | 2015-12-23 | 瑞阳制药有限公司 | 尼索地平胶囊及其制备方法 |
CN111481514A (zh) * | 2019-01-25 | 2020-08-04 | 鲁南制药集团股份有限公司 | 一种治疗高血脂的片剂及其制备方法 |
CN111481514B (zh) * | 2019-01-25 | 2023-01-10 | 鲁南制药集团股份有限公司 | 一种治疗高血脂的片剂及其制备方法 |
CN109694899A (zh) * | 2019-02-20 | 2019-04-30 | 扬州倍加洁日化有限公司 | 一种含有chg成分的湿巾产品中微生物限度的检测方法 |
CN110420191A (zh) * | 2019-09-06 | 2019-11-08 | 北京兴源联合医药科技有限公司 | 一种包含左甲状腺素钠的口腔崩解片 |
CN110563635A (zh) * | 2019-09-19 | 2019-12-13 | 合肥立方制药股份有限公司 | 二氢吡啶类降压药物原料药微粉化的新方法 |
CN110563635B (zh) * | 2019-09-19 | 2021-02-26 | 合肥立方制药股份有限公司 | 二氢吡啶类降压药物原料药微粉化的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102406939B (zh) | 2013-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102406939B (zh) | 提高难溶性药物溶解性能以提高生物利用度的方法 | |
CN104434805B (zh) | 一种替格瑞洛固体分散体及其制备方法 | |
CN103006661B (zh) | 一种含有盐酸鲁拉西酮的制剂及其制备方法 | |
CN107823170A (zh) | 一种缬沙坦氨氯地平片及其制备方法 | |
CN103705520A (zh) | 一种利伐沙班固体组合物的制备方法 | |
CN113577079B (zh) | 一种磷酸二酯酶抑制剂的制备方法及组合物 | |
CN103705510A (zh) | 一种阿齐沙坦固体组合物的制备方法 | |
CN104069500A (zh) | 一种包含乐卡地平的药物组合物 | |
Peng et al. | Polymer/lipid interplay in altering in vitro supersaturation and plasma concentration of a model poorly soluble drug | |
JP5297194B2 (ja) | 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法 | |
CN103655512B (zh) | 一种硝酸芬替康唑阴道软胶囊及其制备方法 | |
CN100379406C (zh) | 一种难溶性药物微丸的制备方法及包含该微丸的制剂 | |
CN103655470A (zh) | 一种度他雄胺自微乳组合物及其制备方法 | |
CN103933004B (zh) | 一种来曲唑片剂及其制备方法 | |
CN115919793A (zh) | 一种奥利司他胶囊制剂及其制备方法 | |
CN116172966A (zh) | 一种纳米晶型固体分散体球形化颗粒及其制备方法和用途 | |
CN114681404B (zh) | 一种瑞格列奈颗粒剂药物组合物及其制备方法 | |
Cavallari et al. | Release of indomethacin from ultrasound dry granules containing lactose-based excipients | |
CN102688274A (zh) | 乳香提取物的固体分散体及其制备方法 | |
CN105456210A (zh) | 一种高生物利用度的阿齐沙坦组合物 | |
CN105902503A (zh) | 一种野菊花保肝微丸的制备方法 | |
CN107753448B (zh) | 一种苯磺贝他斯汀药物组合物的制备方法 | |
CN103381148A (zh) | 包含非那雄胺的固体制剂及其制备方法 | |
CN104971070A (zh) | 替格瑞洛口服纳米组合物 | |
CN106913538A (zh) | 一种醋酸阿比特龙舌下片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 201203, Pudong New Area Zhangjiang hi tech park, Copernicus Lou, No. 2, building 150, Shanghai Applicant after: SHANGHAI SUNTECH PHARMACEUTICAL CO., LTD. Applicant after: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. Address before: 201203 Shanghai city Pudong New Area libing Road No. 306 Applicant before: Shanghai Fosun Pushi Pharmaceutical Technology Co., Ltd. Applicant before: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANGHAI FOSUN PUSHI PHARMACEUTICAL TECHNOLOGY CO., LTD. TO: SHANGHAI SUN-TECH PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 201210 Shanghai Pudong New Area China (Shanghai) free trade test area No. 1999 Zhang Heng Road No. 7 Co-patentee after: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. Patentee after: Shanghai Double Star Thai Pharmaceutical Technology Co., Ltd. Address before: 201203, Pudong New Area Zhangjiang hi tech park, Copernicus Lou, No. 2, building 150, Shanghai Co-patentee before: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. Patentee before: SHANGHAI SUNTECH PHARMACEUTICAL CO., LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210408 Address after: 201210 building 7, 1999 zhangheng Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai Patentee after: SHANGHAI FOSUN XINGTAI PHARMA TECHNOLOGY Co.,Ltd. Patentee after: SHANGHAI FOSUN PHARMACEUTICAL (Group) Co.,Ltd. Patentee after: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP Co.,Ltd. Address before: 201210 building 7, 1999 zhangheng Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai Patentee before: SHANGHAI FOSUN XINGTAI PHARMA TECHNOLOGY Co.,Ltd. Patentee before: SHANGHAI FOSUN PHARMACEUTICAL (Group) Co.,Ltd. |